About us
About us
Join us
Contact us
Corporate social responsibility
Code of conduct
Amryt compliance
Aegerion Consent Decree
Patients and carers
Patients and carers
Homozygous familial hypercholesterolaemia
Lipodystrophy
Epidermolysis bullosa
Acromegaly
Advocacy
Healthcare professionals
Healthcare professionals
Our science
Trials and registries
Expanded access programme
Medical information enquiries
Grants and donations
Product portfolio
Product portfolio
Juxtapid
®
/ Lojuxta
®
▼
Myalept
®
/ Myalepta
®
▼
Mycapssa
®
Pipeline
Report adverse event
Newsroom
Investors
The Company
News
Reports and presentations
Stock information
Events
Corporate governance
AIM Delisting
Contingent Value Rights (CVR) FAQ
Analysts
Contacts and advisors
Business development
About us
About us
Join us
Contact us
Corporate social responsibility
Code of conduct
Amryt compliance
Aegerion Consent Decree
Patients and carers
Patients and carers
Homozygous familial hypercholesterolaemia
Lipodystrophy
Epidermolysis bullosa
Acromegaly
Advocacy
Healthcare professionals
Healthcare professionals
Our science
Trials and registries
Expanded access programme
Medical information enquiries
Grants and donations
Product portfolio
Product portfolio
Juxtapid
®
/ Lojuxta
®
▼
Myalept
®
/ Myalepta
®
▼
Mycapssa
®
Pipeline
Report adverse event
Newsroom
Investors
The Company
News
Reports and presentations
Stock information
Events
Corporate governance
AIM Delisting
Contingent Value Rights (CVR) FAQ
Analysts
Contacts and advisors
Business development
Register for email alerts
Amryt Pharma has been acquired by Chiesi Farmaceutici S.p.A.
View the press release to learn more
.
CLOSE